Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
grade B 12.88 -1.60% -0.21
MESO closed down 1.6 percent on Thursday, June 4, 2020, on 45 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat
Historical MESO trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Narrow Range Bar Range Contraction -1.60%
NR7 Range Contraction -1.60%
Inside Day Range Contraction -1.60%
Narrow Range Bar Range Contraction -3.81%
Narrow Range Bar Range Contraction 0.39%
Inside Day Range Contraction 0.39%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Biotechnology Health Life Sciences Pharmaceutical Industry Stem Cells Therapeutic Products Cardiovascular Diseases Technology Platforms Diabetic Nephropathy Back Pain Host Diseases Mesoblast Regenerative Biomedicine

Is MESO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.57
52 Week Low 3.1201
Average Volume 1,372,389
200-Day Moving Average 7.45
50-Day Moving Average 9.11
20-Day Moving Average 12.41
10-Day Moving Average 12.86
Average True Range 0.99
ADX 52.53
+DI 39.29
-DI 12.27
Chandelier Exit (Long, 3 ATRs ) 11.53
Chandelier Exit (Short, 3 ATRs ) 13.11
Upper Bollinger Band 13.73
Lower Bollinger Band 11.09
Percent B (%b) 0.68
BandWidth 21.23
MACD Line 1.01
MACD Signal Line 1.15
MACD Histogram -0.1456
Fundamentals Value
Market Cap 1.09 Billion
Num Shares 84.9 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -13.28
Price-to-Sales 193.69
Price-to-Book 0.90
PEG Ratio -0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.04
Resistance 3 (R3) 14.11 13.81 13.84
Resistance 2 (R2) 13.81 13.51 13.77 13.78
Resistance 1 (R1) 13.34 13.33 13.19 13.27 13.71
Pivot Point 13.04 13.04 12.96 13.00 13.04
Support 1 (S1) 12.57 12.74 12.42 12.50 12.05
Support 2 (S2) 12.27 12.56 12.23 11.98
Support 3 (S3) 11.80 12.27 11.92
Support 4 (S4) 11.73